Hucog Liquid Form 10000 (HCG 10000iu)

Product Overview

Hucog Liquid Form 10000 is a sterile, ready‑to‑use injectable solution that delivers Human Chorionic Gonadotropin (HCG) at a potency of 10,000 International Units (IU) per vial. The product is manufactured by Bharat Serums and Vaccines Limited, a pharmaceutical company based in India that complies with Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO). Each package contains 10 ml of clear, colorless liquid sealed in a single glass vial with a rubber stopper and aluminum flip‑off cap. The medication is classified under the therapeutic category of female infertility and male hypogonadism, indicating its primary clinical applications in assisted reproductive technologies and hormone replacement therapy. Proper storage requires refrigeration at 2–8 °C and protection from light; freezing is strictly prohibited.

What is Hucog Liquid Form 10000 (HCG 10000iu)

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone produced by the syncytiotrophoblast after implantation of a fertilized egg. Clinically, recombinant HCG is administered exogenously to mimic the endogenous luteinizing hormone (LH) surge that occurs naturally in the menstrual cycle. Hucog Liquid Form 10000 provides a high‑dose, single‑administration option that can be given either intramuscularly or subcutaneously. The formulation is supplied as a sterile liquid, eliminating the need for reconstitution and reducing preparation time. Its pharmacological action is mediated through binding to the LH/hCG receptor on ovarian granulosa cells and Leydig cells, thereby modulating steroidogenesis and gametogenesis.

Uses and Benefits

In reproductive medicine, Hucog is most frequently employed as a trigger for final follicular maturation in controlled ovarian stimulation protocols. A single 10,000 IU dose can induce ovulation in women with ovulatory disorders such as polycystic ovary syndrome (PCOS), idiopathic anovulation, or following ovarian hyperstimulation with gonadotropins. The timing of the injection is critical; it is typically administered when follicles reach a mean diameter of 18–20 mm, as assessed by ultrasound.

For male patients, HCG therapy serves to restore endogenous testosterone production in cases of hypogonadotropic hypogonadism. By stimulating Leydig cells, Hucog can increase serum testosterone levels, improve libido, and support spermatogenesis when combined with appropriate adjunct therapy. Clinical studies have shown that adjunctive HCG therapy can enhance sperm concentration and motility in men with secondary hypogonadism.

Additional off‑label investigations have explored HCG for weight‑loss regimens; however, regulatory agencies such as the FDA have not approved these uses, and they should be approached with caution.

How It Works

Pharmacodynamically, HCG acts as a potent agonist of the LH/hCG receptor. In the ovary, receptor activation triggers a cascade of intracellular second messengers, including cyclic adenosine monophosphate (cAMP), which promotes final oocyte maturation and luteinization. This process culminates in the release of the mature oocyte from the dominant follicle, a critical step for fertilization.

In the testes, HCG binding to the LH receptor on Leydig cells stimulates cholesterol conversion to pregnenolone via the steroidogenic acute regulatory (StAR) protein, initiating the steroidogenic cascade that culminates in testosterone synthesis. Elevated testosterone levels can improve libido, muscle mass, and secondary sexual characteristics, and may facilitate sperm production when paired with appropriate adjunct therapy.

The pharmacokinetic profile of HCG after a 10,000 IU dose shows a terminal half‑life of approximately 28–36 hours, allowing for weekly dosing in many protocols. Metabolism occurs primarily in the liver, with renal excretion of metabolites.

Dosage Guidelines

Dosage must be individualized based on the clinical indication, patient age, baseline hormone levels, and treatment response. The following represents commonly used regimens, but all dosing should be confirmed by a qualified healthcare professional.

• Female infertility: A single intramuscular or subcutaneous injection of 10,000 IU is administered when follicles have reached an optimal size (typically 18–20 mm). In some protocols, a split dose of 5,000 IU administered on two consecutive days may be used to enhance ovulation rates.
• Male hypogonadism: Treatment generally consists of 5,000–10,000 IU administered intramuscularly or subcutaneously once weekly for 8–12 weeks. Serum testosterone levels are monitored at baseline and after 4–6 weeks to guide dose adjustments.

Patients should be instructed to rotate injection sites (abdominal wall, thigh, or upper arm) to minimize tissue irritation. The vial must remain refrigerated at 2–8 °C until use and should never be frozen.

Side Effects

Most adverse reactions to HCG therapy are mild and self‑limiting. Common side effects include:

• Local reactions at the injection site such as pain, erythema, or induration.
• Headache, fatigue, or mild nausea.
• Transient fluid retention, which may manifest as peripheral edema.

Less frequent but clinically significant events include hypersensitivity reactions (urticaria, dyspnea, or anaphylaxis) and thromboembolic phenomena, particularly in patients with pre‑existing risk factors. In the event of severe abdominal pain, swelling, or signs of an allergic reaction, immediate medical evaluation is recommended.

Warnings and Precautions

Prior to initiating therapy, clinicians should assess the following considerations:

• Contraindication in patients with known hypersensitivity to HCG or any excipients in the formulation.
• Use with caution in individuals with hormone‑sensitive cancers, unexplained vaginal bleeding, or ovarian cysts of uncertain etiology.
• Pregnancy testing is recommended for women of reproductive potential before treatment, as inadvertent administration during early pregnancy may affect fetal development.
• Concurrent use of other hormonal medications should be reviewed to avoid supraphysiologic hormone levels.
• Patients should be advised about the risk of multiple gestation in assisted reproduction cycles, as HCG can increase the likelihood of twins or higher‑order multiples.

Healthcare providers should also discuss the potential for allergic reactions and provide instructions on recognizing early signs of hypersensitivity.

FAQs

1. What is the recommended storage condition for Hucog Liquid Form 10000? The vial should be stored refrigerated at 2–8 °C and protected from light. Freezing is strictly prohibited.

2. Can Hucog be self‑administered at home? Yes, after proper training and under physician supervision, patients may self‑inject subcutaneously using a sterile needle and disposable syringe.

3. How soon after injection can ovulation occur? Ovulation typically occurs within 24–48 hours after a single dose, although individual response may vary.

4. Is Hucog safe to use during pregnancy? Hucog is contraindicated for use during pregnancy unless specifically indicated for a medical condition, as it may interfere with fetal hormonal signaling.

5. Where can I purchase Hucog legally? Hucog is a prescription‑only medication; it can be obtained from licensed pharmacies or authorized online retailers that require a valid prescription from a qualified clinician.

For detailed pharmacological information, refer to authoritative sources such as the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and the MedlinePlus drug database. Additional background on the hormone’s physiology and clinical use is available on its Wikipedia entry.

Related Products

• Enoxaparin 300 mg Injection (Generic)
• Enoxaparin 60mg Injection (Generic)
• Lonopin Pen (Only Pen) (Device)
• Lonopin 60mg Injection (Enoxaparin)
• Enoxaparin 40mg Injection (Generic)
• Lonopin 40mg Injection (Enoxaparin)
• Enoxaparin 20mg Injection (Generic)
• Lonopin 20mg Injection (Enoxaparin)
• Lonopin MD 300 mg Injection (Enoxaparin)
• Ovidac (HCG (HUMAN CHORIONIC GONADOTROPIN))
• hCG 10000iu Injection (Human Chorionic Gonadotropin)
• hCG 5000iu Injection (Human Chorionic Gonadotropin)